Comparison of the adverse events to interferon therapy in patients with chronic hepatitis C: standard interferon versus pegylated interferon

DOI Web Site Web Site 3 References
  • Yagura Michiyasu
    Department of Gastroenterology, National Hospital Organization, Tokyo National Hospital
  • Tanaka Akihisa
    Department of Gastroenterology, National Hospital Organization, Tokyo National Hospital
  • Iri Masanobu
    Department of Gastroenterology, National Hospital Organization, Tokyo National Hospital
  • Kamitsukasa Hiroshi
    Department of Gastroenterology, National Hospital Organization, Tokyo National Hospital

Bibliographic Information

Other Title
  • Ｃ型慢性肝炎に対するｉｎｔｅｒｆｅｒｏｎ治療の副作用の比較－従来型ｉｎｔｅｒｆｅｒｏｎとｐｅｇｉｎｔｅｒｆｅｒｏｎ
  • Cガタ マンセイ カンエン ニ タイスル interferon チリョウ ノ フクサヨウ ノ ヒカク ジュウライガタ interferon ト peginterferon

Search this article

Abstract

We compared the adverse events among the same patients with chronic hepatitis C who were treated with standard interferon (IFN) with no response and again treated with pegylated interferon (PEG-IFN) combined with or without ribavirin (RIB), based on a questionnaire and blood count analysis. Patients were divided into four groups; standard IFN group, standard IFN+RIB group, PEG-IFN group, and PEG-IFN+RIB group. As a result, allergic reactions, such as itching, stomatitis, sneezing were much less seen in the standard IFN group, compared to PEG-IFN group. On the other hand, flu-like symptoms were more seen in the former than the latter. Hemoglobin and neutrophilic leukocyte counts significantly decreased until 16 weeks after starting the therapy in the groups with RIB than the groups without it. Platelet level significantly decreased at 2 weeks in the standard IFN+RIB group compared with PEG-IFN+RIB. As a whole, patients were satisfied with PEG-IFN therapy in view of visiting a doctor only once a week and its physical and mental easiness.<br>

Journal

  • Kanzo

    Kanzo 49 (6), 275-278, 2008

    The Japan Society of Hepatology

References(3)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top